Details checkedClinical trial listing onlyCheckedtrial

Isosorbide Oral Solution by Lunan Better Pharmaceutical

Also known as: Isosorbide oral solution, BT-YSLC-001

Lunan Better Pharmaceutical Co., Ltd.

Primary source

Company

Lunan Better Pharmaceutical Co., Ltd.

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2/3

Status

Active

Target Gene

—

Route / Mode

Oral solution

Confidence

88%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-08

Geography

China; exact site list not available in local registry snapshot

Population

adult, unilateral, meniere-disease

Trial IDs

Mechanism

Oral osmotic diuretic/vasoactive therapy being evaluated against placebo for unilateral Meniere disease, an inner-ear disorder associated with fluctuating hearing symptoms, tinnitus, and vertigo.

Indications

Hearing Loss Tinnitus

Notes

Verified active registry-backed Meniere disease program. ClinicalTrials.gov identifies a randomized Phase II/III study of isosorbide oral solution in unilateral Meniere disease sponsored by Lunan Better Pharmaceutical.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, company, stage, status, route, indications, populationTags, trialIds...

IDs: NCT06765993, BT-YSLC-001, Isosorbide oral solution

Open

Key Events

2025-01-09

ClinicalTrials.gov posted the BT-YSLC-001 isosorbide oral solution Phase II/III Meniere disease study

Clinical Trials (1)

NCT06765993

Data Checks